# NOV 25 2005

# 510(k) SUMMARY for Inion S-1<sup>TM</sup> Biodegradable Anterior Cervical Fusion System

### MANUFACTURER

Inion Ltd., Lääkärinkatu 2, FIN-33520 Tampere, FINLAND

#### **Contact Person**

Hanna Marttila, Regulatory Affairs Director Lääkärinkatu 2, FIN-33520 Tampere Phone: +358 3 2306 600

Fax: +358 3 2306 691 hanna.marttila@inion.com

#### **DEVICE NAME**

Trade name: Inion S-1<sup>TM</sup> Biodegradable Anterior Cervical Fusion System

### ESTABLISHMENT REGISTRATION NUMBER

9710629

#### DEVICE CLASSIFICATION AND PRODUCT CODE

Class: II

Classification Panel: Orthopedic

Regulation number: 21 CFR 888.3060

Regulation name: Appliance Fixation, Spinal Intervertebral Body

Product Code: KWQ

Regulation number: 21 CFR 888.3040

Regulation name: Smooth or threaded metallic bone fixation fastener

Product Code: HWC

#### PREDICATE DEVICES

MacroPore OS Spinal System K010911 MacroPore Hydrosorb Spine System K041105

#### CONFORMANCE WITH PERFORMANCE STANDARDS

No applicable mandatory performance standards exist for this device. Compliance to voluntary consensus standards is listed in the application.

## DEVICE DESCRIPTION AND PRINCIPLES OF OPERATION

Inion S-1<sup>TM</sup> Biodegradable Anterior Cervical Fusion System, in conjunction with traditional rigid fixation (i.e., posterior interspinous wiring), is intended for use in cervical spinal fusion procedures as a means to maintain the relative position of weak bony tissue such as allografts and autografts. This device is not intended for load bearing indications.

Inion S-1 TM Biodegradable Anterior Cervical Fusion System consist of cervical spinal fusion plates and screws, and is made of resorbable polylactic acid copolymers, P(L/DL)LA 80:20.

Based on in vitro testing: Inion S-1 Biodegradable Anterior Cervical Fusion System retain most of it's strength up to 16 weeks and gradually loose it's strength thereafter; and bioresorption takes place within two to four years.

Inion S-1 TM Biodegradable Anterior Cervical Fusion System is provided sterile to the user and is non-pyrogenic. The shelf life of the device is 3 years.

## SUBSTANTIAL EQUIVALENCE TO MARKETED PRODUCTS

Based on the performance data and specifications presented, it can be concluded that the intended use, material composition and scientific technology, degradation profile and mechanical properties of Inion S-1 <sup>TM</sup> Biodegradable Anterior Cervical Fusion System are substantially equivalent with the predicate devices MacroPore *OS* Spinal System (K010911) and MacroPore Hydrosorb Spine System (K041105).

Inion S-1 <sup>TM</sup> Biodegradable Anterior Cervical Fusion System is substantially equivalent to predicate Class II devices used in conjunction with traditional rigid fixation (i.e., posterior interspinous wiring) in cervical spinal fusion procedures as a means to maintain the relative position of weak bony tissue such as allografts and autografts, because the differences between Inion S-1 <sup>TM</sup> Biodegradable Anterior Cervical Fusion System and the predicate devices do not raise new questions of safety and effectiveness.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ms. Hanna Marttila Regulatory Affairs Director Inion, Ltd. Laakarinkatu 2 FIN-33520 Tampere, Finland

NOV 2 3 2005

Re: K051821

Trade/Device Name: S-1 Biodegradable Anterior Cervical Fusion System

Regulation Number: 21 CFR 888.3060

Regulation Name: Spinal intervertebral body fixation orthosis

Regulatory Class: Class II Product Code: KWQ, HWC

Dated: June 30, 2005 Received: July 5, 2005

Dear Ms. Marttila:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

#### Page 2 – Hanna Marttila

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <a href="http://www.fda.gov/cdrh/industry/support/index.html">http://www.fda.gov/cdrh/industry/support/index.html</a>.

Sincerely yours,

Mark N. Melkerson

**Acting Director** 

Division of General, Restorative,

and Neurological Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

### **Indications for Use**

510(k) Number (if known): K051821

Device Name:

Inion S-1<sup>TM</sup> Biodegradable Anterior Cervical Fusion System

Indications for Use:

#### **INDICATIONS**

The INION S-1<sup>TM</sup> BIODEGRADABLE ANTERIOR CERVICAL FUSION SYSTEM, in conjunction with traditional rigid fixation (i.e., posterior interspinous wiring), is intended for use in cervical spinal fusion procedures as a means to maintain the relative position of weak bony tissue such as allografts and autografts. This device is not intended for load bearing indications.

#### CONTRAINDICATIONS

The INION S-1<sup>TM</sup> BIODEGRADABLE ANTERIOR CERVICAL FUSION SYSTEM implants are not intended for use in and are contraindicated for:

- Load bearing indications unless used in conjunction with traditional rigid fixation.
- Active or potential infection.
- Patient conditions including limited blood supply, insufficient quantity or quality of bone; and where patient cooperation cannot be guaranteed (e.g., alcoholism, drug abuse).

Prescription Use Yes (Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use No (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)

Division of General, Restorative, and Neurological Devices

510(k) Number K051821